You are here: > Resources > Allison M. Zieve Esq.

Allison M. Zieve Esq.

Self Description

March 2012: "Allison M. Zieve joined Public Citizen Litigation Group in August 1994. In 2009, she became the Group's director and director of our Supreme Court Assistance Project. She also serves as General Counsel of Public Citizen. Ms. Zieve’s litigation practice areas include public health (such drug safety and food labeling issues), consumer safety (such as automobile standards), open government, federal preemption, class action abuse, and First Amendment issues (in the context of federal regulation and of the Internet). Many of her cases involve issues related to the Food, Drug, and Cosmetic Act and to regulation by the Food and Drug Administration. She has also litigated against the National Highway Traffic Safety Administration, the Department of Justice, and the Department of Health and Human Services, among other agencies. Among the cases litigated by Ms. Zieve are Riegel v. Medtronic, Inc., 552 U.S. 312 (2008) (preemption of state tort law), Warner-Lambert Co. v. Kent, 552 U.S. 440 (2008) (preemption of provision of Michigan product liability law), Will v. Hallock, 126 U.S. 952 (2006) (Federal Tort Claims Act), and Dusenbery v. United States, 534 U.S. 161 (2002) (due process).

Ms. Zieve serves as a member of the Administrative Conference of the United States and teaches as an adjunct professor at Georgetown University School of Law. She also serves as a trustee of the Client Security Fund of the District of Columbia Bar. In addition, since its inception, Ms. Zieve has judged the American Constitution Society's Richard D. Cudahy Writing Competition on Regulatory and Administrative Law. She has written articles for N.Y.U.’s Annual Survey of American Law, Duke Law School’s Law & Contemporary Problems, TRIAL Magazine, various BNA legal publications, Internal Medicine News, and Regulatory Affairs Journal (UK).

Ms. Zieve is admitted to the District of Columbia Bar and is admitted to practice before numerous federal courts. She was graduated from Brown University and Yale Law School."

Third-Party Descriptions

March 2012: 'Public Citizen, a consumer advocacy group, has petitioned the Food and Drug Administration to give generic companies greater control over their labels, a rule change that could allow users of generic drugs to sue, but the agency said earlier this month that it needed more time to decide. “Congress can make this problem go away, and the F.D.A. could, too,” said Allison Zieve, the director of Public Citizen Litigation Group.'


RoleNameTypeLast Updated
Student/Trainee (past or present) Brown University Organization Mar 28, 2012
Employee/Freelancer/Contractor (past or present) Georgetown University Organization Mar 28, 2012
Organization Executive (past or present) Public Citizen Organization Mar 28, 2012
Student/Trainee (past or present) Yale University Organization Mar 28, 2012

Articles and Resources

Date Resource Read it at:
Mar 20, 2012 Generic Drugs Proving Resistant to Damage Suits

QUOTE: Across the country, dozens of lawsuits against generic pharmaceutical companies are being dismissed because of a Supreme Court decision last year that said the companies did not have control over what their labels said and therefore could not be sued for failing to alert patients about the risks of taking their drugs. Now, what once seemed like a trivial detail — whether to take a generic or brand-name drug — has become the deciding factor in whether a patient can seek legal recourse from a drug company.

New York Times